Investigational GLP-1 and glucagon dual agonist peptide
GLP-1/glucagon dual agonist
A dual GLP-1/glucagon agonist in development, studied for weight loss and metabolic effects primarily in Asian populations.
- Evidence:
- Limited human evidence
- Status:
- Investigational
- Reviewed:
- 2026-08-03
Also known as: IBI362, GLP-1/glucagon dual agonist
What is GLP-1/glucagon dual agonist?
A dual GLP-1/glucagon agonist in development, studied for weight loss and metabolic effects primarily in Asian populations.
This profile is educational. It organizes publicly discussed research context for GLP-1/glucagon dual agonist and related naming aliases — it is not a treatment guide.
Proposed mechanism
Dual activation of GLP-1 (satiety, glycemic) and glucagon (energy expenditure, hepatic fat) receptors.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Limited human evidence
Preclinical evidence grade: Moderate human evidence
Mazdutide (IBI362) has reported meaningful weight loss in phase 2 trials in China. Researchers have studied it as a metabolic dual agonist similar in concept to survodutide and retatrutide components. Human evidence remains limited and region-specific; global regulatory status is investigational.
Key uncertainties
- Generalizability outside studied populations
- Phase 3 outcomes pending
Research areas being studied
- Obesity
- Type 2 diabetes
- Metabolic syndrome
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Nausea
- Vomiting
- Diarrhea
Additional risks & considerations
- GI effects
- Limited global trial data
- Glucagon-axis cardiovascular considerations
Regulatory status
Investigational
Investigational; primarily developed in China.
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is GLP-1/glucagon dual agonist?
A dual GLP-1/glucagon agonist in development, studied for weight loss and metabolic effects primarily in Asian populations.
How does GLP-1/glucagon dual agonist work (proposed mechanism)?
Dual activation of GLP-1 (satiety, glycemic) and glucagon (energy expenditure, hepatic fat) receptors.
What is GLP-1/glucagon dual agonist being researched for?
GLP-1/glucagon dual agonist has been discussed in research contexts including: Obesity, Type 2 diabetes, Metabolic syndrome.
What does current evidence say about GLP-1/glucagon dual agonist?
Limited human evidence. Mazdutide (IBI362) has reported meaningful weight loss in phase 2 trials in China. Researchers have studied it as a metabolic dual agonist similar in concept to survodutide and retatrutide components. Human evidence remains limited and region-specific; global regulatory status is investigational.
What safety considerations are noted for GLP-1/glucagon dual agonist?
Reported or discussed considerations include: Nausea; Vomiting; Diarrhea; GI effects; Limited global trial data; Glucagon-axis cardiovascular considerations. This is educational information, not medical advice.
Is GLP-1/glucagon dual agonist FDA approved?
Investigational. Investigational; primarily developed in China.
References & sources
- Ji L et al. (2023). Efficacy and safety of mazdutide in Chinese adults with overweight or obesity — Nat Med. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for GLP-1/glucagon dual agonist or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.